LINAC radiosurgery treatment for vestibular schwannoma

The aims of our study were to evaluate tumour response in a series of patients with vestibular schwannoma (VS) treated with linear accelerator stereotactic radiosurgery (LINAC-RS), to describe the complications and to analyze the variables associated with the response to treatment. This retrospectiv...

Full description

Saved in:
Bibliographic Details
Published in:Neurocirugía (Barcelona. Internet. English ed.) 2019-07, Vol.30 (4), p.179-187
Main Authors: Ros-Sanjuán, Ángela, Iglesias-Moroño, Sara, Troya-Castilla, Marta, Márquez-Márquez, Bernarda, Herruzo-Cabrera, Ismael, Arráez-Sánchez, Miguel Ángel
Format: Article
Language:English
Subjects:
Acelerador lineal
LINAC-RS
Linear accelerator
Radiocirugía estereotáxica
Rc-LINAC
Schwannoma vestibular
Stereotactic radiosurgery
Vestibular schwannoma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aims of our study were to evaluate tumour response in a series of patients with vestibular schwannoma (VS) treated with linear accelerator stereotactic radiosurgery (LINAC-RS), to describe the complications and to analyze the variables associated with the response to treatment. This retrospective descriptive study included 64 patients treated from 2010 to 2016 with a minimum follow-up of one year, excluding patients with neurofibromatosis. Clinical–radiological parameters were evaluated. The treatment was performed using LINAC-RS. The prescribed dose was 12Gy at 90% isodose. The mean age at treatment was 53 years, 56% were women. Ninety-eight percent of the patients had hearing loss, 71% with grade III according to the Gardner–Robertson Classification. The mean volume at treatment was 2.92cc and the mean follow-up, 40.95 months. The overall therapeutic success was 90%, reaching 100% at 12 and 24 months, and 86% after 36 months of follow-up. The radiological result was significantly related to the initial tumour volume (p
ISSN:2529-8496
2529-8496
DOI:10.1016/j.neucie.2018.12.003